新股消息 | 丹诺医药递表港交所 拥有利福特尼唑(TNP-2198)等三大核心产品

智通财经
Jul 31
【新股消息 | 丹诺医药递表港交所 拥有利福特尼唑(TNP-2198)等三大核心产品】智通财经APP获悉,据港交所7月30日披露,丹诺医药(苏州)股份有限公司(简称:丹诺医药)向港交所主板递交上市申请,中信证券和农银国际为联席保荐人。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10